Advances in Therapy · 2019 · 45 citations · 9 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibacterial PharmacotherapyAntibacterial TherapyAntibiotic ResistanceAntimicrobial TherapyCarbapenem ResistanceCombination Antimicrobial Therapy28-Day MortalityCarbapenem AntibioticsKlebsiella Pneumoniae CarbapenemaseKlebsiella Pneumoniae ResistanceMicrobiological CureOutcome MeasuresPost Hoc Subgroup AnalysisTreatment Of Bacterial Resistance
INTRODUCTION: Infections due to Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are associated with increased morbidity and high mortality. Meropenem-vaborbactam (MV) is a novel β-lactam/β-lactamase inhibitor combination active against KPC-producing Enterobacteriaceae. The aim of this post hoc analysis of the TANGO-II randomized controlled trial was to assess the efficacy of MV versus best available therapy (BAT) in the subgroup of patients without prior antimicrobial failure. METHODS: The primary outcome measure was clinical cure at the test of cure (TOC). Secondary outcome measures included (1) clinical cure at the end of therapy (EOT), (2) microbiological cure at TOC, (3) microbiological cure at EOT, and (4) 28-day all-cause mortality. RESULTS: First-line MV was associated with a 42.9% absolute increase in clinical cure rate at TOC (95% confidence intervals [CI] 13.7-72.1) in comparison with first-line BAT. A 49.3% absolute increase in clinical cure rate at EOT (95% CI 20.8-77.7), a 42.6% absolute increase in microbiological cure rate at EOT (95% CI 13.4-71.8), and a 36.2% absolute increase in microbiologic cure rate at TOC (95% CI 5.9-66.6) were also observed, in addition to a 29.0% absolute reduction in mortality (95% CI - 54.3 to - 3.7). Overall, fewer adverse events were observed in the MV group than in the BAT group. CONCLUSION: MV was superior to BAT in the subgroup of patients with serious carbapenem-resistant Enterobacteriaceae (CRE) infections and no prior antimicrobial failure, with very high rates of clinical success, and was well tolerated. Post approval and real-world studies remain essential to clearly define the most appropriate population for early, empirical MV coverage, in accordance with antimicrobial stewardship principles. FUNDING: The Medicines Company.
9
Brian T. Tsuji, Jason M. Pogue, Alexandre Prehn Zavascki et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2019 · 931 citations · Full text
George L. Daikos, Sophia Tsaousi, L. S. Tzouvelekis et al. · Antimicrobial Agents and Chemotherapy · 2014 · 602 citations · Full text
Mario Tumbarello, Enrico Maria Trecarichi, Francesco Giuseppe De Rosa et al. · Journal of Antimicrobial Chemotherapy · 2015 · 512 citations · Full text
Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav et al. · Infectious Diseases and Therapy · 2018 · 442 citations · Full text